ADXN

Addex Therapeutics Ltd. ADXN

NasdaqSmall CapHealthcare

13F Pro Quality Score

Not in ranked universe

Below size threshold

Below the main board's size threshold of $25M annual revenue or $100M total assets. This company reported $0.0M in revenue and is scored on the micro-cap board instead.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

Revenue

$30.0K

Quarter to Dec 31

Net income

$-6.73M

Quarter to Dec 31

Free cash flow

$-2.17M

Quarter to Dec 31

Top Institutional Holders

as of Q2 2026
$274 total
UBS Group AG
$268New
SBI Securities Co., Ltd.
$60.0%
See all 2 institutional holders →
Reading the latest SEC filing…

Key Metrics

Revenue

FY 2025
EDGAR

Net Income

FY 2025
EDGAR

EPS (Diluted)

FY 2025
EDGAR

ROIC

FY 2025
EDGAR

Free Cash Flow

FY 2025
EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/ADXN

Earnings Per Share

13fpro.ai/company/ADXN

Loading ratio trend…

ADXN key financials by period

Reported revenue, net income and operating margin by fiscal year, from Addex Therapeutics Ltd.'s annual filings on SEC EDGAR.

Addex Therapeutics Ltd. reported revenue, net income and margins by fiscal period, from SEC filings.
PeriodRevenueNet incomeOp. margin
FY 2025$30.0K$-6.7M—
FY 2024$404.1K$7.1M—
FY 2023$1.6M$-10.6M-139.1%
FY 2022$1.4M$-20.8M—
FY 2021$2.9M$-15.4M—
FY 2020$3.6M$-12.9M—
Source: ADXN filings on SEC EDGAR →

ADXN insiders

Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.

About Addex Therapeutics Ltd. (ADXN): stock profile, AI score and financials

Addex Therapeutics Ltd. (ADXN) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. ADXN is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $0.0m in revenue and is scored on the micro-cap board instead. Based on the latest XBRL financial filings (FY 2025), Addex Therapeutics Ltd. reports quarterly revenue of $30.0K, net income of $-6.7M, free cash flow of $-2.2M. ADXN trades on the Nasdaq exchange and files with the SEC under CIK 1574232. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ADXN daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Addex Therapeutics Ltd. directly from SEC EDGAR.

Financials through the period ended SEC EDGAR: CIK 1574232 →